SI-BONE posted adjusted EBITDA of $2.8 million for Q2, a 178 % jump from the prior year, delivering its first positive EBITDA figure. The profit swing improves cash generation and narrows the $4.1 million net loss, giving investors confidence in the company’s emerging profitability trajectory.

Key Highlights

  • Worldwide revenue $56.0 million grew 15.2% YoY, driven by U.S. sales up 14.7%
  • Net loss narrowed to $4.1 million, a 33.6% improvement versus last year
  • Physician network expanded to 1,715 doctors, a 19% increase year‑over‑year

SI-BONE (NASDAQ: SIBN) reported adjusted EBITDA of $2.8 million for the quarter ended June 30, a 178 % increase from the same period a year earlier and its first positive EBITDA figure. Revenue climbed to $56.0 million, up 15.2% YoY, while the net loss shrank to $4.1 million, a 33.6% improvement. The results beat the consensus EPS estimate of $‑0.15, delivering $‑0.09 per diluted share.

This earnings beat and profitability milestone provide a tangible lift to the company’s cash‑flow outlook, a factor that could reshape valuation models ahead of the upcoming earnings call.

178% EBITDA Surge

The company’s adjusted EBITDA leapt from $1.0 million in the prior year to $2.8 million, reflecting a 178 % jump that stems from higher procedure volumes and better margin capture. Gross profit rose 14.8% to $44.5 million, supporting a gross margin of 79.5%, only a fraction below the prior 79.8% rate. Despite higher expenses, operating loss improved 31.4% to $4.8 million, reinforcing the trend toward profitability.

The positive cash flow from operations of $0.8 million, combined with cash and equivalents of $145.9 million, underscores a solid liquidity base that buffers the company against short‑term volatility.

Revenue and Margin Drivers

U.S. revenue of $53.2 million grew 14.7% YoY, accounting for the bulk of the $56.0 million worldwide total, while international sales rose 25.9% to $2.8 million on the back of iFuse TORQ adoption. Procedure volume in the United States increased 14.9%, fueling a 5% rise in average revenue per territory to $2.2 million. The physician base expanded to 1,715 active doctors, a 19% jump that expands market reach and supports sustainable top‑line growth.

Gross margin held steady at 79.5%, indicating that pricing power and cost efficiencies remain intact despite higher volumes. These dynamics suggest that the revenue lift is not merely seasonal but reflects deeper adoption of the company’s procedural platform.

Market Reaction and Positioning

Short interest sits at 12% of float with 8.9 days of average volume to cover, signaling moderate skepticism but not an overt squeeze. Sector peers ASST and AVR edged higher 0.3% and 0.8% respectively, indicating that the broader medical‑device space is holding steady while SI‑BONE’s earnings beat provides a relative edge. The improvement in earnings and cash generation could attract value‑oriented investors seeking exposure to a niche orthopedic platform with rising profitability.

Upcoming Catalyst

The call will be webcast live and archived for 90 days, offering analysts ample opportunity to probe the impact of the upcoming third‑breakthrough device slated for a fourth‑quarter launch.

Peers Moving on This News

  • Strive Inc (ASST) up 0.3%
  • Anteris Technologies Global Corp (AVR) up 0.8%

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.